Safety, immunogenicity and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV®) and measles or measles-mumps-rubella vaccines in 8–9 months-old Indian children

References

• Mukhopadhyay B, Sur D, Gupta SS, Ganguly NK. Typhoid fever: control & challenges in India. Indian J Med Res. 2019;150(5):437–9. doi:10.4103/ijmr.IJMR_411_18.
   PubMed Web of Science ®Google Scholar
• GBD 2017 Typhoid and Paratyphoid Collaborators. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis. 2019;19(4):369–81. doi:10.1016/S1473-3099(18)30685-6.
   PubMed Web of Science ®Google Scholar
• Institute for Health Metrics and Evaluation. Typhoid fever – level 4 cause. [accessed 2022 Oct 30]. https://www.healthdata.org/results/gbd_summaries/2019/typhoid-fever-level-4-cause.
   Google Scholar
• Crump JA. Progress in typhoid fever epidemiology. Clin Infect Dis. 2019;68(Suppl 1):S4–9. doi:10.1093/cid/ciy846.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC). National typhoid and paratyphoid fever surveillance annual summary, 2015. Atlanta (GA): US Department of Health and Human Services, CDC; 2018 [accessed 2022 Oct 30]. https://www.cdc.gov/typhoid-fever/reports/annual-report-2015.html.
   Google Scholar
• WHO. Typhoid vaccines: WHO position paper – March 2018. Weekly Epidemiological Record. 2018;93:153–72.
   Google Scholar
• WHO. Prequalification of medical products (IVDs, medicines, vaccines and immunization devices, vector control) – Typbar-TCV. [accessed 2022 Oct 30]. https://extranet.who.int/pqweb/content/typbar-tcv.
   Google Scholar
• Vadrevu Krishna Mohan, Varanasi V, Singh A, Pasetti MF, Levine MM, Venkatesan R, Ella KM . Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clin. Infect. Dis. 2015;61(3):393–402. doi:10.1093/cid/civ295.
   PubMed Web of Science ®Google Scholar
• TyVAC. Take on typhoid – typhoid vaccines. [accessed 2022 Oct 30]. https://www.coalitionagainsttyphoid.org/the-issues/typhoid-vaccines/.
   Google Scholar
• Singh K, Mehta S. The clinical development process for a novel preventive vaccine: an overview. J Postgrad Med. 2016;62(1):4–11. doi:10.4103/0022-3859.173187.
   PubMed Web of Science ®Google Scholar
• Yousafzai MT, Karim S, Qureshi S, Kazi M, Memon H, Junejo A, Khawaja Z, Rehman NU, Ansari MS, Ali R, et al. Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study. Lancet Glob Health. 2021;9(8):e1154–62. doi:10.1016/S2214-109X(21)00255-2.
   PubMed Web of Science ®Google Scholar
• Patel PD, Patel P, Liang Y, Meiring JE, Misiri T, Mwakiseghile F, Tracy JK, Masesa C, Msuku H, Banda D, et al. Safety and efficacy of a typhoid conjugate vaccine in Malawian children. N Engl J Med. 2021;385(12):1104–15. doi:10.1056/NEJMoa2035916.
   PubMed Web of Science ®Google Scholar
• Nampota-Nkomba N, Nyirenda OM, Khonde L, Mapemba V, Mbewe M, Ndaferankhande JM, Msuku H, Masesa C, Misiri T, Mwakiseghile F, et al. Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial. Lancet Glob Health. 2022;10(9):e1326–35. doi:10.1016/S2214-109X(22)00275-3.
   PubMed Web of Science ®Google Scholar
• Shakya M, Colin-Jones R, Theiss-Nyland K, Voysey M, Pant D, Smith N, Liu X, Tonks S, Mazur O, Farooq YG, et al. Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal. N Engl J Med. 2019;381(23):2209–18. doi:10.1056/NEJMoa1905047.
   PubMed Web of Science ®Google Scholar
• Shakya M, Voysey M, Theiss-Nyland K, Colin-Jones R, Pant D, Adhikari A, Tonks S, Mujadidi YF, O’Reilly P, Mazur O, et al. Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial. Lancet Glob Health. 2021;9(11):e1561–68. doi:10.1016/S2214-109X(21)00346-6.
   PubMed Web of Science ®Google Scholar
• Sirima SB, Ouedraogo A, Barry N, Siribie M, Tiono AB, Nébié I, Konaté AT, Berges GD, Diarra A, Ouedraogo M, et al. Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: a randomized controlled phase 2 trial. Int J Infect Dis. 2021;108:465–72. doi:10.1016/j.ijid.2021.05.061.
   PubMed Web of Science ®Google Scholar
• Sirima SB, Ouedraogo A, Barry N, Siribie M, Tiono AB, Nébié I, Konaté AT, Berges GD, Diarra A, Ouedraogo M, et al. Safety and immunogenicity of co-administration of meningococcal type a and measles–rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso. Int J Infect Dis. 2021;102:517–23. doi:10.1016/j.ijid.2020.10.103.
   PubMed Web of Science ®Google Scholar
• Olaru ID, Mtapuri-Zinyowera S, Feasey N, Ferrand RA, Kranzer K. Typhoid Vi-conjugate vaccine for outbreak control in Zimbabwe. Lancet Infect Dis. 2019;19(9):930. doi:10.1016/S1473-3099(19)30425-6.
   PubMed Web of Science ®Google Scholar
• Lightowler MS, Manangazira P, Nackers F, Van Herp M, Phiri I, Kuwenyi K, Panunzi I, Garone D, Marume F, Tarupiwa A, et al. Effectiveness of typhoid conjugate vaccine in Zimbabwe used in response to an outbreak among children and young adults: a matched case control study. Vaccine. 2022;40(31):4199–210. doi:10.1016/j.vaccine.2022.04.093.
   PubMed Web of Science ®Google Scholar
• Qadri F, Khanam F, Liu X, Theiss-Nyland K, Biswas PK, Bhuiyan AI, Ahmmed F, Colin-Jones R, Smith N, Tonks S, et al. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. Lancet. 2021;398(10301):675–84. doi:10.1016/S0140-6736(21)01124-7.
   PubMed Web of Science ®Google Scholar
• WHO. Safety of typhoid conjugate vaccine. [accessed 2022 Oct 30]. https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/typhoid-vaccines.
   Google Scholar
• WHO. Guidance on co-administration of typhoid vaccine with measles-containing vaccines.[accessed 2022 Oct 30]. https://cdn.who.int/media/docs/default-source/immunization/multiple-injections/coadministration_of_tcv_with_mcv_15aug2018.pdf?sfvrsn=ff9f92df_7.
   Google Scholar
• WHO – SAGE. Background paper to SAGE on typhoid vaccine policy recommendations. [accessed 2022 Oct 30]. https://cdn.who.int/media/docs/default-source/immunization/position_paper_documents/typhoid/1-typhoid-sage-background-paper-final-v3b.pdf?sfvrsn=ddf418c3_2.
   Google Scholar
• Yu JC, Khodadadi H, Malik A, Davidson B, Salles ÉDSL, Bhatia J, Hale VL, Baban B. Innate immunity of neonates and infants. Front Immunol. 2018;9:1759. doi:10.3389/fimmu.2018.01759.
   PubMed Web of Science ®Google Scholar
• Vadrevu KM, Raju D, Rani S, Reddy S, Sarangi V, Ella R, Javvaji B, Mahantshetty, NS, Battu, S, Levine, MM. Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination. Vaccine. 2021;39(45):6682–6690. doi:10.1016/j.vaccine.2021.07.073.
   PubMed Web of Science ®Google Scholar